[1] |
ZHENG Yi, LUO Xiao, ZHANG Pengpeng, LIU Yongmei, YE Xiaofei, GUO Xiaojing, CHEN Xia, HE Jia.
Adverse reactions of immune checkpoint inhibitor myocarditis based on active monitoring system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 634-638.
|
[2] |
YE Pei, ZHANG Hewei, LYU Qiang, YE Xiaofei, XU Jinfang, GUO Xiaojing.
Safety of sugammadex for reversal of neuromuscular block based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 321-325.
|
[3] |
ZHAO Yan, LI Dong, CHENG Yinjie, JIANG Bin, ZHAO Yifei, DONG Fang, YUAN Jing.
Advances in studies on post-market safety data sources and signal detection for medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 236-240.
|
[4] |
HAO Xiaohui, ZHANG Ping, WU Lulu, WANG Lihua.
Mining and analysis of ixazomib citrate capsules safety signals based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1427-1431.
|
[5] |
WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan.
Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089.
|
[6] |
SUN Yixin, LIU Zhike, ZHAN Siyan.
Scoping review of near real-time surveillance of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 61-67.
|
[7] |
LIU Zhike, ZHAN Siyan.
Progress in applications of self-controlled designs in association study of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 74-78.
|
[8] |
REN Yuqin, LI Xin, YU Min, SU Yuwen.
Safety evaluation and comparative analysis of rituximab and adalimumab based on openFDA
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 752-756.
|
[9] |
ZHANG Chi.
Data mining of adverse drug events of alirocumab from openFDA
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 684-691.
|
[10] |
CUI Xiangli, ZHANG Zhiqi, SUN Liying, GUO Mingxing, ZENG Zhigui, XU Wanyi.
Leflunomide-induced hepatotoxicity: data analysis based on the FDA adverse event reporting system
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 426-431.
|
[11] |
ZHAO Xiaohong, GUO Mingxing, WANG Xiaojian, LIN Jianrui, CUI Xiangli.
Risk signal mining related to lenvatinib based on the US FDA adverse event reporting system
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1233-1237.
|
[12] |
SHA Mingquan, LI Nannan, XIA Wenjing, WEI Qun, WEN Baoshu.
Research and reflection on regulatory science developments of U.S. FDA
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1055-1059.
|
[13] |
LING Tao, XU Ruijuan, GE Weihong.
Comparison Analysis of Adverse Drug Reactions of Rivaroxaban and Apixaban Based on OpenFDA
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 780-783.
|
[14] |
WEI Fuqian, ZHANG Wei, YANG Yue.
Drug Risk Communication between Drug Regulatory Agencies and the Public
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(10): 949-952.
|
[15] |
LI Jiangfan, HU Ye, PANG Hongxian, ZHAO Dan, LI Xinru, WANG Xuhong.
Comparative Analysis of Adverse Drug Reactions of Evolocumab and Alirocumab Based on OpenFDA
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(10): 965-968.
|